International Clinical Trial: An Open Label Single Dose Two Period Oral Bioequivalence Study Comparing Upadacitinib 45 mg Extended Release Tablets in Healthy Adult Human Subjects Under Fed Conditions

Geneva, May 4 -- International Clinical Trials Registry received information related to the study (CTRI/2026/04/109078) titled 'An Open Label Single Dose Two Period Oral Bioequivalence Study Comparing Upadacitinib 45 mg Extended Release Tablets in Healthy Adult Human Subjects Under Fed Conditions' on April 22.

Study Type: BA/BE

Study Design: Randomized, Crossover Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Pharmacy-controlled Randomization Blinding and masking:Open Label

Primary Sponsor: Bajaj Healthcare Limited

Intervention: Intervention1: Upadacitinib 45 mg Extended Release Tablets: A Single oral dose of Upadacitinib 45 mg Extended Release Tablets will be...